Navigation Links
Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/3/2009

JERUSALEM, September 3 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that Nadav Kidron, its Chief Executive Officer, is scheduled to present at the Rodman & Renshaw's 11th Annual Healthcare Conference on Friday September 11, 2009 at 10:00 a.m. EDT. The conference will be held at the New York Palace Hotel in New York City.

Nadav Kidron is scheduled to speak in the Fahnestock Salon on the fifth floor of the hotel. He will discuss Oramed's strategic initiatives, updates and product pipeline.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, tim
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
4. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
5. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
6. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
7. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Pomerantz LLP is investigating claims on behalf of investors ... IPXL).  Such investors are advised to contact Robert ... ext. 237. The investigation concerns whether Impax ... Sections 10(b) and 20(a) of the Securities Exchange Act ... Impax Laboratories, Inc. (the "Company") issued a press release ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014 TransVac Solutions, the ... collection and transport solutions for hospitals, will be exhibiting ... Engineering (ASHE) Annual Conference & Technical Exhibition Aug. 3-6 ... its technology for making hospitals cleaner, reducing infection risk ... the hospital’s life cycle. Staff will be available ...
(Date:7/29/2014)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) dramatically ... investment in Green Chemistry and donated more than 8,000 ... the Company announced Monday in its new 2013 ... The report comes in a year ... responsible corporate citizen, including recognition for the second consecutive ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... present during the 11th Annual BIO CEO & Investor,Conference ... The presentation,will be webcast from the Waldorf-Astoria Hotel ... To access the presentation via the Web, please go ...
... Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) ... and year ended December 31, 2008. , ... to $31.2 million,compared with $19.3 million in the fourth quarter ... assay was $30.9 million in the fourth,quarter of 2008, an ...
... Feb. 3 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., ... has obtained CE Mark approval for its Neurostep(TM) ... system (CLS) used on peripheral nerves. CE Mark ... the Neurostep(TM) in any of the Member States ...
Cached Biology Technology:Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 2Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3
(Date:7/29/2014)... an easier method to create DNAprotein conjugates. The ... diagnosing diseases. , DNA linked to proteins ... can be used in diagnostic techniques, nanotechnology and ... with DNA can be used for purposes ... biological material. The method also provides easier access ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
(Date:7/29/2014)... to go and almost 2500 registered participants, the final ... The event, a joint venture between the Federation of ... for Biochemistry and Molecular Biology (SFBBM), will take place ... the Palais des Congrs in Paris, France. , The ... life sciences in Europe this year. It features more ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Counting down to FEBS-EMBO 2014 in Paris, France 2
... fattening than others? What about the risks of bariatric ... (ASN) on December 5-7 for answers to these questions ... Nutrition Conference. The 3-day program delivers valuable ... satellite sessions, and networking opportunities. Credentialed media, science writers ...
...   The Bensalem Township Police Department , in conjunction with ... of DNA testing.  This pilot program known as " BodeHITS ... kind in the country for law enforcement. Bensalem ... with over 6,000 DNA profiles consisting of evidence and reference/individual ...
... , Nov. 19, 2013 Nelson Laboratories ( www.nelsonlabs.com ... (#321) during BIOMEDevice in San ... Thor Rollins, biocompatibility specialist. Those interested in a consultation ... http://photos.prnewswire.com/prnh/20120727/LA47745LOGO ) Rollins will also present, ...
Cached Biology News:Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 290 Minute DNA Results, A First Of Its Kind, Coming To Bensalem 2Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose 2
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
... Convenient platform for tube handling and reagent dispensing ... tubes - 96 x 0.3ml U-bottom ... - Thermo-Fast® 96 Non-Skirted Plate - ... x 0.5ml Thermo-Tubes Multiple workstations can be securely stacked ...
6B9...
Biology Products: